Phase I clinical trials to assess its safety, human tolerance, and pharmacokinetic properties. XW10172 is the first compound that Kerry Corning has independently developed in innovative drug pipelines to enter clinical research and is expected to become a new generation of first-line drugs for the treatment of narcolepsy.

Narcolepsy is a rare, chronic neurological disease in which the patient's sleep-wakefulness is circadian and disorderly, characterized by symptoms such as excessive daytime sleepiness and cataplexy.

Currently, medications for treating drowsiness are usually only for one of the above-mentioned symptoms.

Kerry Corning's R&D team designed a new intellectual property compound XW10172 based on the existing treatment for first-line narcolepsy, which showed superior pharmacokinetic characteristics and drug-like properties compared to the original study drug in preclinical studies.

XW10172 is expected not only to effectively treat the main symptoms of narcolepsy, but also to improve the convenience and compliance of medications to achieve better results.

Kerry Corning has used its three drug development platforms to establish a diverse R&D pipeline for the treatment of central nervous system diseases.

Kerry Corning's first and second platforms aim to develop best-in-class drugs that have the potential to be used to treat new indications; and its third platform is a new one focused on reducing mitochondrial damage.

The R & D platform and the loss of mitochondrial function have been found to be closely associated with a variety of neurodegenerative diseases.